Metrics as of 10/15/2026, 08:31 AM (Berlin time), refresh in progress.
4D Molecular Therapeutics Stock
4D Molecular Therapeutics, Inc.
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- CEO
- David H. Kirn
- Employees
- 196
- Market cap
- $674 M
- IPO
- 11/12/2020
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology…
4D Molecular Therapeutics stock: price history
1D
-1.3%
1W
-3.1%
1M
-11.3%
6M
+24.9%
YTD
+62.7%
1Y
+22.4%
2Y
+35.1%
5Y
-55.3%
10Y
–
Next earnings date
Next earnings date
10/11/2026 (in 24 days)
Volatility around earnings
~3% weaker price swings than usual
4D Molecular Therapeutics stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 18/09/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
4D Molecular Therapeutics is a clinical-stage biotechnology company specializing in the development of gene therapies using proprietary AAV vector technology. The company focuses on the therapeutic areas of ophthalmology, cardiology, and pulmonology. Currently, several drug candidates are in Phase 1/2 clinical trials for the treatment of diseases such as retinitis pigmentosa and Fabry disease. Revenue generation is currently driven by licensing fees and research collaborations with partners. The business model is characterized by high research intensity and a focus on developing patent-protected therapeutic approaches.
- Revenue model
- Transactional
- Recurring revenue
- Low
- Pricing power
- Strong
- Moat
- Narrow
- Moat type
- Brand / IP
- Capital intensity
- High
- Customer concentration
- Unknown
Suppliers & customers in our universe
uniQure N.V.Description
Roche Holding AGDescriptionAsk the agents about 4D Molecular Therapeutics
Analyst assessment of 4D Molecular Therapeutics
PRICE TARGET LOW
US$20.00
CONSENSUS
US$29.67
MEDIAN
US$32.00
PRICE TARGET HIGH
US$37.00
0
STRONG BUY
11
BUY
2
HOLD
1
SELL
0
STRONG SELL
14
TOTAL · Buy
As of: 06/10/2026
4D Molecular Therapeutics stock metrics
P/E
-4.49
P/B
2.1
EV/EBITDA
-3.49
RETURN ON EQUITY
-17.9%
NET MARGIN
-1,929.0%
DEBT/EQUITY
0.1
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
77.0%
FLOAT SHARES
42,553,511
AVG. DAILY VOLUME (30D)
970,851
Insider transactions (SEC)
Kirn David
Kirn David
Bizily Scott
Bizily Scott
Kirn David
Institutional holders
Comparable stocks
Frequently asked questions about 4D Molecular Therapeutics stock
What does 4D Molecular Therapeutics do?
4D Molecular Therapeutics, Inc. is a company in the Healthcare sector, Biotechnology industry, headquartered in United States.
The CEO is David H. Kirn, the company employs around 196 people.
The IPO was on 11/12/2020; the stock trades on NASDAQ under the ticker FDMT.
What do analysts say about 4D Molecular Therapeutics stock?
14 analysts rate the stock, the consensus is Buy (as of 06/10/2026).
The average price target is US$29.67, ranging from US$20.00 to US$37.00, with a median of US$32.00.
This is an external assessment, not a statement by Market Jury.
When does 4D Molecular Therapeutics report next?
The next earnings date is 10/11/2026.
Around past earnings, price swings were roughly -3% stronger than usual.
Does 4D Molecular Therapeutics pay a dividend?
No, 4D Molecular Therapeutics currently does not pay a dividend.
Which stocks are comparable to 4D Molecular Therapeutics?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, Revolution Medicines, Incyte, Exelixis, Neurocrine Biosciences and Summit Therapeutics.
How can I get 4D Molecular Therapeutics stock analyzed?
Clicking "Analyze stock" lets five strategies assess 4D Molecular Therapeutics against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.